5.24
Precedente Chiudi:
$5.21
Aprire:
$5.21
Volume 24 ore:
540.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.87B
Reddito:
$563.46M
Utile/perdita netta:
$27.92M
Rapporto P/E:
54.36
EPS:
0.0964
Flusso di cassa netto:
$-146.33M
1 W Prestazione:
-2.60%
1M Prestazione:
+38.99%
6M Prestazione:
+35.05%
1 anno Prestazione:
-34.74%
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ALVO
Alvotech
|
5.24 | 1.86B | 563.46M | 27.92M | -146.33M | 0.0964 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-11-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Iniziato | UBS | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-09-21 | Iniziato | Barclays | Equal Weight |
| 2022-09-07 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Downgrade | Citigroup | Buy → Sell |
| 2022-07-26 | Iniziato | Citigroup | Buy |
Mostra tutto
Alvotech Borsa (ALVO) Ultime notizie
What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media
Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - marketbeat.com
Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP
Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - marketbeat.com
FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net
Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance
Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance
Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st
Alvotech to present at upcoming investor conferences in September - finance.yahoo.com
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st
BofA starts bullish Alvotech coverage on biosimilar launch cycle - Investing.com
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - pulse2.com
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang
Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha
Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat
Alvotech Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com
ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView
Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance
Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo
Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView
Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade
Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade
Alvotech Azioni (ALVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):